Biosimilars have revolutionized the biopharmaceutical industry since they first appeared a little over a decade ago. They are medical products that are highly similar to an already approved reference product. In order for a biosimilar to be approved, the developer needs to demonstrate similarity to the reference product in key areas, such as pharmacokinetics, pharmacodynamics and evaluate efficacy, safety and immunogenicity in clinical studies.